Are you Dr. Rasco?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 99 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4383 Medical Dr
Fl 3
San Antonio, TX 78229Phone+1 210-593-5700Fax+1 210-593-5992- Is this information wrong?
Summary
- Dr. Drew Rasco, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and Georgia. He is affiliated with Methodist Hospital and Northeast Baptist Hospital.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
The University of Texas Health Science Center at San AntonioClass of 2003
Certifications & Licensure
TX State Medical License 2008 - 2024
GA State Medical License 2005 - 2009- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Start of enrollment: 2011 Sep 12
- Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone Start of enrollment: 2013 May 01
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Start of enrollment: 2015 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma> ;Investigational New Drugs. 2024 Mar 14
- Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-...Carla Biesdorf, Xiaowen Guan, Satya R Siddani, Nils Boehm, Bruno C Medeiros, Toshihiko Doi, Maja de Jonge, Drew Rasco, Rajeev M Menon, Akshanth R Polepally, David Hoffman> ;Cancer Chemotherapy and Pharmacology. 2024 Apr 1
- 2 citationsFirst-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.Nehal J Lakhani, Drew Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Tommy Fu, Mary C Collins, Ping Min, Yan Yin, Matthew S Davids, Dajun Yang, Yifan Zhai> ;Clinical Cancer Research. 2024 Feb 1
- Join now to see all
Press Mentions
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific ProgramMay 29th, 2020
START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
MEDIAN Technologies and START Expand Relationship to Three New Centers in Grand Rapids, MI and Madrid, SpainJune 30th, 2016- Join now to see all
Hospital Affiliations
Methodist HospitalSan Antonio, Texas- Northeast Baptist HospitalSan Antonio, Texas
